Search results :

5-azacytidine

More information: STITCH, PubChem (stereo-specific compound: 1) and possibly Wikipedia

ATC Code: L01BC07

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8
Thrombocytopenia very common, 3.2% - 69.7% x x x x x x x x
Anaemia very common, 2.3% - 69.5% x x x x x x x x
Body temperature increased very common, 0.98% - 51.8% x x x x x x x x
Asthenia 20.7% - 29.1% x x x x x x
Cough 15.2% - 29.5% x x x
Neutropenia very common, 2.7% - 65.7% x x x x x x x x
Rigors 10.9% - 25.5% x x x x x x
Nausea very common, 0% - 70.5% x x x x x x x x
Ecchymosis very common, 15.2% - 30.5% x x x x x x x x
Anorexia very common, 6.52% - 20.5% x x x x x x x x
Arthralgia very common, 3.26% - 22.3% x x x x x x x x
Chest pain very common, 5.43% - 16.4% x x x x x x x x
Diarrhoea very common, 14.1% - 36.4% x x x x x x x x
Dizziness very common, 5.43% - 18.6% x x x x x x x x
Fatigue very common, 1.96% - 35.9% x x x x x x x x
Headache very common, 10.9% - 21.8% x x x x x x x x
Leukopenia very common, 0.98% - 48.2% x x x x x x x x
Oedema peripheral 10.9% - 18.6% x x x
Nasopharyngitis very common, 3.26% - 14.5% x x x x x x x x
Back pain 7.61% - 18.6% x x
Epistaxis 9.78% - 16.4% x x x
Pain in extremity 5.43% - 20% x x
Abdominal pain very common, 0% - 15.5% x x x x x x x x
Pitting edema 9.78% - 14.5% x x
Dyspnoea very common, 1.96% - 29.1% x x x x x x x x
Skin lesion 8.7% - 14.5% x x x x x
Pallor 7.61% - 15.5% x x
Pneumonia very common, 2.5% - 10.9% x x x x x x x x
Decreased appetite 8.7% - 12.7% x x
Febrile neutropenia very common, 2.7% - 16.4% x x x x x x x x
Contusion common, 9.78% - 18.6% x x x x x x x x
Rash common — 0% - 14.1% x x x x x x x x
Depression 7.61% - 11.8% x x
Cardiac murmur 8.7% - 10% x x
Petechiae very common, 0% - 23.6% x x x x x x x x
Rales 8.64% - 10.5% x x
Fatigue aggravated 4.35% - 12.7% x x
Pruritus common — 0% - 12.3% x x x x x x x x
Productive cough 4.35% - 11.4% x x
Constipation very common, 0% - 50.3% x x x x x x x x
Pharyngitis common, 7.61% - 20% x x x x x
Tachycardia 6.52% - 8.64% x x
Pain 3.26% - 10.9% x x x x x
Vomiting very common, 0% - 54.1% x x x x x x x x
Abdominal pain upper 3.26% - 10.5% x x
Abdominal tenderness 1.09% - 11.8% x x x x x
Pleural effusion 6.36% - 6.52% x x
Lymphadenopathy 3.26% - 9.55% x x
Peripheral swelling 5.43% - 7.27% x x
Sweating increased 2.17% - 10.5% x x
Cellulitis 4.35% - 8.18% x x x x x x x
Rhinorrhoea 2.17% - 10% x x
Night sweats 3.26% - 8.64% x x
Syncope 5.43% - 5.91% x x
Oral mucosal petechiae 3.26% - 7.73% x x
Anaemia NOS aggravated 5.43% - 5.45% x x x x x
Herpes simplex common, 5.43% - 9.09% x x x x x
Wheezing 2.17% - 8.64% x x
Dysuria 2.17% - 8.18% x x
Abdominal distension 4.35% - 5.91% x x
Alopecia common x x x
Confusional state common x x x x x
Conjunctival haemorrhage common x x x
Eye haemorrhage common x x x x x x
Gastrointestinal haemorrhage common, 0.8% x x x x x x x x
Gingival bleeding common, 4.35% - 9.55% x x x x x x x x
Haematoma common, 0% - 8.64% x x x x x x x x
Haemorrhage common x x x x x x x
Hypokalaemia common, 1.71% - 13% x x x x x x x x
Hypotension common, 2.17% - 6.82% x x x x x x x x
Inflammation common x x x
Musculoskeletal pain common x x x
Nodule common x x x
Pancytopenia common x x x x x x
Purpura common x x x
Sinusitis common, 3.26% - 5% x x x x x
Stomatitis common, 0% - 7.73% x x x x x x x x
Urinary tract infection common, 0% - 8.57% x x x x x x x x
Weight decreased common, 0% - 15.9% x x x x x x x x
Haemorrhage intracranial common, 0.5% x x x x x x x x
Rash macular common x x x
Malaise common, 1.09% - 10.9% x x x x x x x x
Myalgia common, 2.17% - 15.9% x x x x x x x x
Dyspnoea exertional common, 0% - 16.3% x x x x x x x x
Haemorrhoidal haemorrhage common x x x
Induration common x x x
Neutropenic sepsis common, 0.8% x x x x x x
Cramp muscle 3.26% - 5.91% x x
Postnasal drip 3.26% - 5.91% x x
Respiratory sounds decreased 1.09% - 7.73% x x
Dyspepsia common, 0% - 6.82% x x x x x x x x
Erythema common, 0% - 16.8% x x x x x x x x
Upper respiratory tract infection common, 0% - 12.7% x x x x x x x x
Insomnia common, 0% - 10.9% x x x x x x x x
Dyspnoea exacerbated 3.26% - 5% x x
Rhonchi 2.17% - 5.91% x x
Haemorrhoids 1.09% - 6.82% x x
Hypertension common, 1.14% - 8.57% x x x x x x
Atelectasis 2.17% - 5% x x
Dysphagia 2.17% - 5% x x
Tongue ulceration 2.17% - 5% x x
Post procedural pain 2.17% - 5% x x
Urticaria 1.09% - 5.91% x x x x x
Post procedural haemorrhage 1.09% - 5.91% x x x x x
Transfusion reaction 0% - 6.82% x x x
Injection site pruritus 0% - 6.82% x x x x x
Nasal congestion 1.09% - 5.45% x x
Anxiety common, 0% - 13.2% x x x x x x x x
Hypoaesthesia 1.09% - 5% x x
Mouth haemorrhage 1.09% - 5% x x x x x
Skin nodule 1.09% - 5% x x x x x
Dry skin 1.09% - 5% x x x x x
Pharyngolaryngeal pain common, 0% - 6.29% x x x x x x
Loose stools 0% - 5.45% x x x x x
Chest wall pain 0% - 5% x x x x x
Injection site granuloma 0% - 5% x x x x x
Injection site swelling 0% - 5% x x x x x
Injection site pigmentation changes 0% - 5% x x x x x
Haematuria common, 0.98% - 6.29% x x x x x x x x
Lethargy common, 0% - 7.73% x x x x x x x x
Rhinitis common, 0% - 5.71% x x x x x x
Injection site reaction very common, 0% - 29.1% x x x x x x x x
Hypersensitivity uncommon, 0.25% x x x x x x x x
Tumour lysis syndrome postmarketing x x x x x x
Acute febrile neutrophilic dermatosis postmarketing x x x x
Injection site necrosis postmarketing x x x x x x
Interstitial lung disease postmarketing x x x x x x
Renal tubular acidosis x x x x x x x x
Agranulocytosis x x x x x
Anaphylactic shock x x x x x
Refractory anaemia with an excess of blasts x x
Atrial fibrillation x x x x x
Bacterial infection x x x x x
Mental disorder x x x x x x x x
Blastomycosis x x x x x
Bronchitis x
Congestive cardiomyopathy x x x x x
Neck pain x x x x x
Cholecystitis x x x x x
Coma x
Infection x x x x x x x x
Connective tissue disorder x x x x x x x x
Cyst x
Dehydration x x x x x
Diverticulitis x x x x x
Eye disorder x x x x x x
Gastrointestinal disorder x x x x x x x x
Cardiac disorder x x x x x
Cardiac failure x x x x x
Cardiac failure congestive x x x x x
Haemoptysis x x x x x
Coma hepatic x x x x x x x x
Orthostatic hypotension x x x x x
Immune system disorder x x x x x x x x
Mediastinal disorder x x x x x x x x
Melaena x x x x x
Neoplasm x x x x x x x x
Nervous system disorder x x x x x x x x
Polyp x
Prurigo x x x x x
Renal failure x x x x x x x x
Convulsion x x x x x
Pharyngitis streptococcal x x x x x
Septic shock x x x
Splenomegaly x x x x x
Staphylococcal infection x x x x x
Toxoplasmosis x x x x x
Urinary tract disorder x x x x x x x x
Angiopathy x x x x x x x x
Hepatic failure x
Pyoderma gangrenosum x x x x x
Bone marrow depression x x
Muscular weakness x x x x x
Injection site pain very common, 0% - 22.7% x x x x x x x x
Staphylococcal bacteraemia x x x x x
Malnutrition x x x x x x x x
Unspecified disorder of skin and subcutaneous tissue x x x x x x x x
Fatal outcomes x
Injection site infection x x x x x
Loin pain x x x x x
Lung infiltration x x x x x
Skin induration x x x x x
Systemic inflammatory response syndrome x x x x x
Sepsis x x x x x
Perirectal abscess x x x x x
Hepatobiliary disease x x x x x x
Refractory anemia with excess blasts in transformation x x
Respiratory distress x x x x x
Pneumonia klebsiella x x x x x
Injection site dermatitis 0% - 5.71% x x x x x x
Injection site bruising 0% - 14.1% x x x x x
Injection site induration 0% - 5.14% x x x
Injection site haematoma 0% - 6.29% x x x
Bone pain aggravated x x x x x
Abscess limb x x x x x
Cardio-respiratory arrest x x x x x
Klebsiella sepsis x x x x x
Infestation NOS x x x x x x x x
Blood and lymphatic system disorders x x x x x x x x
Injection site erythema very common, 0% - 42.9% x x x x x x x x
General physical health deterioration x x x x x
Catheter site haemorrhage x x x x x
Catheter site erythema x
Leukaemia cutis x x x x x
Infusion site reactions x x x x
Cerebral haemorrhage x x x x
Metastatic disease x x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

azacitidine / azacitidine

Side effects:98
Source:EMA

03 October 2013 / Vidaza (azacitidine) Powder for Injection

Side effects:103
Source:medicines.org.au

Azacitidine

Side effects:143
Source:FDA Structured Product Label

AZACITIDINE

Side effects:145
Source:FDA Structured Product Label

AZACITIDINE

Side effects:146
Source:FDA Structured Product Label

AZACITIDINE / VIDAZA

Side effects:170
Source:FDA

AZACITIDINE / VIDAZA

Side effects:172
Source:FDA

Color scheme:

standardalternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label